Editorial

The Hajj pilgrimage and surveillance for Middle East Respiratory syndrome coronavirus in pilgrims from African countries

Alimuddin Zumla1,2,3,4, Peter Mwaba2, Matthew Bates2,3, Jaffar A. Al-Tawfiq1,5, Markus Maeurer6 and Ziad A. Memish1

1 Global Centre for Mass Gatherings Medicine, Ministry of Health, Riyadh, Saudi Arabia
2 UNZA-UCLMS Research and Training Programme, University Teaching Hospital, Lusaka, Zambia
3 Division of Infection and Immunity, University College London, London, UK
4 UCL Hospitals NHS Foundation Trust, London, UK
5 Saudi Aramco Medical Services Organization, Saudi Aramco, Dhahran, Saudi Arabia
6 Therapeutic Immunology Division, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden

keywords MERS-CoV, Respiratory tract infections, Africa, Hajj, Screening, camels, coronavirus

It is well documented that mass gatherings attracting people from all over the world create an ideal environment for rapid transmission and spread of viral and bacterial respiratory infections (Abubakar et al. 2012). Africa has a large Muslim population estimated at over 250 million (Government 2011). Every year, more than 1 million pilgrims from African countries travel to Makkah and Madinah, Kingdom of Saudi Arabia (KSA) to join 10 million other pilgrims from around the globe to perform either the annual Hajj pilgrimage (Figure 1) or the Umrah, which can be performed at any time of the year (Memish et al. 2014a). One of the major public health concerns related to these journeys is the importation on arrival, or exportation on departure, of a range of infectious diseases, some of which may have epidemic potential (Al Rabeeah et al. 2012; Al-Tawfiq & Memish 2012). For example, Rift Valley fever from East Africa caused outbreaks in KSA and Yemen (Fagbo 2002), and there have been two important meningococcal disease outbreaks in KSA related to the Hajj (al-Gahtani et al. 1995; Aguilera et al. 2002).

The past 15 years have seen the emergence of several killer respiratory tract infectious diseases with epidemic potential that generated global health alerts from WHO. Notable threats have come from avian influenza viruses, the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and, more recently, the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and multidrug-resistant tuberculosis (Lee et al. 2003; Al-Tawfiq et al. 2013; Zumla et al. 2013b). The 2012 and 2013 Hajj pilgrimages were of major international concern because of the appearance in September 2012 of a new human pathogen, the Middle East respiratory syndrome coronavirus (MERS-CoV), first isolated from a patient in Jeddah, KSA, who died of a severe respiratory illness (Zaki et al. 2012). The appearance of this new, initially rapidly fatal infectious disease of unknown origin, and the uncertainty about its mode of transmission quickly focussed political and scientific attention, especially when MERS cases were detected in the UK, France, German and Italy (Zumla 2014). Contact and droplet transmission are the most likely route of human-to-human transmission of MERS-CoV, and people with medical comorbidities are more likely to succumb to the disease (WHO 2014a). MERS-CoV causes disease in all age and gender groups and can present as a spectrum of clinical presentations from the asymptomatic, to mild and more severe, rapidly fatal

Figure 1 Absolute numbers of pilgrims traveling from different countries in Africa, stratified by year during period from 2010–2013.

© 2014 John Wiley & Sons Ltd Tropical Medicine and International Health doi:10.1111/tmi.12318 volume 19 no 7 pp 838–840 July 2014
illness (Assiri et al. 2013; Memish et al. 2014b; WHO 2014a).

The crucial missing epidemiological link is the source of MERS-CoV and mode of transmission from the reservoir to humans (Zumla 2014). Apart from KSA, MERS cases have been linked to six other countries in the Middle East: Jordan, Kuwait, Oman, Qatar, Tunisia and the United Arab Emirates, indicating that a widespread reservoir of MERS-CoV must exist in the Arabian Gulf. The search to find an animal source has implicated bats and dromedary camels as possible reservoirs of MERS-CoV. A study from KSA reported detection of a short nucleotide sequence the faeces of the bat *Taphozous perforatus*, which was identical to that of MERS-CoV isolated from the index human MERS case in Jeddah, KSA (Memish et al. 2014b). Several betacoronaviruses genetically closely related to MERS-CoV have been isolated from the faeces of South African bats (Memish et al. 2013). There is growing evidence from several studies that dromedary camels may be playing an important role in MERS-CoV transmission to humans. Serological studies have found MERS-CoV antibodies in camels in Jordan, Tunisia, Ethiopia, Nigeria, Egypt, Saudi Arabia, Canary Islands and UAE, and MERS-CoV has been detected in camels from Qatar, Saudi Arabia and Egypt (Hemida et al. 2013; Reusken et al. 2013; Alagaili et al. 2014; Alexandersen et al. 2014; Haagmans et al. 2014), lending strong support to the hypothesis that transmission is likely occurring from camels to humans, infection occurring either directly or indirectly through consumption of contaminated food or contaminated fomites. Several important epidemiological questions regarding the distribution and determinants of MERS-CoV infection in humans arise:

- As of March 1st 2014, nearly 2 years after MERS-CoV was first discovered, there have been a total of 180 cases of MERS-CoV infection with a 46% mortality rate reported worldwide to the WHO. All cases have had links to the Middle East, and the majority of cases (151 with 62 deaths (41% mortality) have been reported from KSA as of March 5, 2014. Does MERS-CoV only affect populations in the Middle East or is it also prevalent in countries in Africa, Asia, Australia and South America where camels are present?
- Does this focus on the Middle East represent a bias in case detection due to a high degree of awareness and governments having a more proactive screening programme for MERS-CoV?
- Is there evidence of association with the genetic make-up of Middle Eastern populations that would make people more or less susceptible to infection with MERS-CoV, as reported for other infectious diseases (Blackwell et al. 2009; Apps et al. 2013)?
- What role does co-infection with other respiratory disease pathogens play in clinical presentations of MERS-CoV (Rizzo et al. 2010; Redford et al. 2014)?
- When was MERS-CoV actually introduced into human populations and how did it cross the species barrier?

During the 2012 and 2013 Hajj pilgrimages, 5 million pilgrims from 184 countries (including 500 000 from African countries) visited Makkah and Madinah in KSA, and no cases of MERS-CoV were detected during their stay in KSA or after the pilgrims returned home. As both camels and bats are found in all parts of Africa, there is a high likelihood of MERS-CoV infections being missed. There is certainly a lack of awareness of MERS-CoV across the African continent and beyond the Middle East amongst healthcare workers. Furthermore, diagnostic services for respiratory viral infections are virtually non-existent at most entry points in the health system and are scanty at referral centres.

In response to the potential threat of an influenza pandemic, several international institutions and governments, in partnership with 15 African countries, invested in the development of epidemiologic and laboratory influenza surveillance capacity in Africa, and the African Network of Influenza Surveillance and Epidemiology (ANISE) was formed (Kasolo et al. 2013). The project ‘Strengthening Influenza Sentinel Surveillance in Africa (SISA)’ is currently generating epidemiological and virological data and developing routine national, regional and international reporting mechanisms (Kebede et al. 2013) in liaison with WHO, national influenza laboratories and other stakeholders involved in influenza surveillance. This initiative must be extended to screening for MERS-CoV. A large percentage of pilgrims return to their home countries after the Hajj pilgrimage with symptoms of respiratory tract infections. Thus, there is a dire need for developing rapid diagnostic platforms for screening of multiple pathogens in patients presenting with acute respiratory tract infections at all points of care (Zumla et al. 2013a) so accurate and early identification can be made, allowing for appropriate treatment and infection control measures to be accorded. Meanwhile, it is important that a more proactive search for MERS-CoV infections is performed by healthcare workers in African countries using current guidelines for MERS-CoV screening and testing (CDC 2014; WHO 2014b) and that they keep a high degree of awareness of the possibility of MERS-CoV infection in all patients presenting with RTIs.
References

Abubakar I, Gautret P, Brunette GW et al. (2012) Global perspectives for prevention of infectious diseases associated with mass gatherings. The Lancet Infectious Diseases 12, 66–74.

Aguilera JF, Perrocheau A, Meffre C et al. (2002) Outbreak of seegroup W135 meningococcal disease after the Hajj pilgrimage, Europe 2000. Emerging Infectious Diseases 8, 761–767.

Al Rabeeah A, Memish ZA, Zumla A et al. (2012) Mass gatherings and infectious diseases: prevention, detection, and control. Infectious Disease Clinics of North America 26, 725–737.

Al-Tawfiq JA & Memish ZA (2012) Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio 5, e00884–14.

Alexandersen S, Kobinger GP, Soule G et al. (2014) Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005. Transboundary and Emerging Diseases 61, 105–108.

Al-Tawfiq JA & Memish ZA (2012) Mass gatherings and infectious diseases: prevention, detection, and control. Infectious Disease Clinics of North America 26, 725–737.

Al-Tawfiq JA, Smallwood CA, Arbuthnott KG et al. (2013) Emerging respiratory and novel coronavirus 2012 infections and mass gatherings. Eastern Mediterranean Health Journal 19(Suppl 1), S48–S54.

Apps R, Qi Y, Carlson JM et al. (2013) Influence of HLA-C expression level on HIV control. Science 340, 87–91.

Assiri A, McGeer A, Perl TM et al. (2013) Hospital outbreak of Middle East respiratory syndrome coronavirus. New England Journal of Medicine 369, 407–416.

Blackwell JM, Jamieson SE & Burgnier D (2009) HLA and infectious diseases. Clinical Microbiology Reviews 22, 370–385, Table of Contents.

CDC (2014) Middle East Respiratory Syndrome (MERS) [Online]. CDC, Atlanta. Available: http://www.cdc.gov/coronavirus/mers/ Accessed 6 March 2014.

Fagbo SF (2002) The evolving transmission pattern of Rift Valley fever in the Arabian Peninsula. Annals of the New York Academy of Sciences 969, 201–204.

Haagmans BL, Al-Dahabry SH, Reusken CB et al. (2014) Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. The Lancet Infectious Diseases 14, 140–145.

Hemida MG, Perera RA, Wang P et al. (2013) Middle East Respiratory Syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia 2010 to 2013. Eurosurveillance Weekly 18, 20659.

Kasolo F, Yoti Z, Bakyaita N et al. (2013) IDSR as a platform for implementing IHR in African countries. Biosecurity and Bioterrorism 11, 163–169.

Kebede S, Conteh IN, Steffen CA et al. (2013) Establishing a national influenza sentinel surveillance system in a limited resource setting, experience of Sierra Leone. Health Research Policy and Systems 11, 22.

Lee N, Hui D, Wu A et al. (2003) A major outbreak of severe acute respiratory syndrome in Hong Kong. New England Journal of Medicine 348, 1986–1994.

Memish ZA, Mishra N, Olival KJ et al. (2013) Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerging Infectious Diseases 19, 1819–1823.

Memish ZA, Zumla A, Alhakeem R et al. (2014a). The Annual Haj Pilgrimage: Infectious Disease Surveillance and Control. Lancet in press.

Memish ZA, Al-Tawfiq JA, Makhdoum HQ et al. (2014b). Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study. Clinical Microbiology and Infection doi:10.1111/1469-0691.12562. [Epub ahead of print].

Redford PS, Mayer-Barber KD, McNab FW et al. (2014) Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. Journal of Infectious Diseases 209, 270–274.

Reusken CB, Haagmans BL, Muller MA et al. (2013) Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. The Lancet Infectious Diseases 13, 859–866.

Rizzo C, Caporali MG & Rota MC (2010) Pandemic influenza and pneumonia due to Legionella pneumophila: a frequently underestimated coinfection. Clinical Infectious Diseases 51, 115.

WHO (2014a). Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Summary and Literature Update–as of 20 January 2014. WHO, Geneva.

WHO (2014b) Revised interim case definition for reporting to WHO – Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [Online]. WHO, Geneva. Available: http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/. Zaki AM, van Boheemen S, Bestebroer TM et al. (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New England Journal of Medicine 367, 1814–1820.

Zumla AI (2014) Middle East Respiratory Syndrome Coronavirus – Epidemiologic Potential or ’Storm in a Teacup’. European Respiratory Journal. [Epub ahead of print].

Zumla A, George A, Sharma V et al. (2013a) WHO’s 2013 global report on tuberculosis: successes, threats, and opportunities. Lancet 382, 1765–1767.

Zumla A, Gant V, Bates M et al. (2013b) Rapid diagnostics urgently needed for killer infections. The Lancet Respiratory Medicine 1, 284–285.